Summary
The supplied FDA label excerpt supports the approved uses (AD dementia; mild-to-moderate PDD) and specific transdermal once-daily administration. However, no label support was provided for the majority of the claims, which focus on rivastigmine tartrate cost and purchasing logistics rather than FDA-labeled indications/dosing for Rivastigmine Transdermal System.
Category Scores
Accurate Statements
Rivastigmine tartrate is an older cholinesterase inhibitor used for dementia.
Only partially supported/indeterminable from the provided label excerpt because the label provided is for Rivastigmine Transdermal System and the excerpt does not discuss “older,” “cholinesterase inhibitor,” or “tartrate” form.
Unsupported Statements
The exact cost of rivastigmine tartrate depends on formulation (capsules vs. oral solution vs. transdermal patch).
FDA label excerpt provided contains no information about pricing/cost by formulation.
Rivastigmine tartrate is the salt form used in some oral products.
The provided label excerpt does not mention rivastigmine tartrate or salt forms.
Rivastigmine tartrate cost depends on strength and dosing schedule.
No pricing/cost information is included in the provided label excerpt.
Rivastigmine tartrate cost depends on the pharmacy and location.
No pricing/cost information is included in the provided label excerpt.
Rivastigmine tartrate cost depends on whether the patient pays cash or uses insurance/discount programs.
No pricing/cost information is included in the provided label excerpt.
Rivastigmine tartrate cost depends on whether a generic is available for the exact strength/form being purchased.
No pricing/cost information is included in the provided label excerpt.
Pricing can change frequently by strength and product type.
No pricing/cost information is included in the provided label excerpt.
If buying a generic rivastigmine tartrate product, the patient usually pays less than for any brand version.
No pricing/cost comparative statements are included in the provided label excerpt.
The difference in cost between generic and brand versions of rivastigmine tartrate can vary by pharmacy and by insurance coverage.
No pricing/cost comparative or variability statements are included in the provided label excerpt.
Pricing of rivastigmine tartrate can differ across strengths and manufacturers.
No pricing/cost information is included in the provided label excerpt.
Discount pricing can be meaningfully lower than list price, especially if the patient is uninsured or underinsured.
No pricing/discount guidance or comparative magnitude statements are included in the provided label excerpt.
Cash price comparison for the exact rivastigmine tartrate product strength/formulation can help determine cost.
No pricing guidance is included in the provided label excerpt.
Pharmacy discount programs and prescription discount sites may provide lower pricing.
No pricing/discount-program guidance is included in the provided label excerpt.
The pharmacist may be able to run an alternative NDC if multiple generics exist for the same strength.
The provided label excerpt does not discuss NDC switching or pharmacist processes.
Patent/exclusivity is typically not the main driver of current pricing for rivastigmine products because they are older and largely generic.
The provided label excerpt does not discuss patents/exclusivity or drivers of pricing.
Competition among generic manufacturers usually keeps costs down for largely generic rivastigmine products.
The provided label excerpt does not discuss market dynamics or pricing drivers.
Contradictions
Important Omissions
For the first claim about use in dementia: clarification that the FDA-approved indication for Rivastigmine Transdermal System includes dementia of the Alzheimer’s type (with efficacy demonstrated in mild, moderate, and severe Alzheimer’s disease) and mild-to-moderate dementia associated with Parkinson’s disease; the provided statement is broader and does not include the PDD severity qualifier.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims are primarily about pricing/logistics and do not provide dosing instructions; based on the provided label excerpt, only limited indication/administration content is relevant, and no direct dosing/safety errors are stated in the provided claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Unaligned
Primary Issue
Most claims concern rivastigmine tartrate pricing, insurance/discount programs, NDC switching, and market dynamics, none of which are addressed in the provided FDA label excerpt. The dementia use claim is also too broad and not tied to the label’s specific indications (including mild-to-moderate PDD).
Suggested Improvement
Limit claims to FDA-labeled information for Rivastigmine Transdermal System (approved indications: AD dementia; mild-to-moderate PDD dementia) and, if discussing administration, specify once-daily transdermal patch use with replacement every 24 hours as stated in the label. Remove or clearly label any non-FDA content about cost and purchasing logistics as external/unverified information.